Type of information: Production agreement
Compound: lentiviral vectors used to generate CTL019 (tisagenlecleucel) and other undisclosed Chimeric Antigen Receptor T cell (CART) products
Company: Novartis (Switzerland) Oxford Biomedica (UK)
Therapeutic area: Cancer - Oncology - Technology - Services
Type agreement: production - manufacturing
Action mechanism: cell therapy/gene therapy/CAR-T cell therapy.
- • On July 6, 2017, Oxford BioMedica announced that it has signed an agreement with Novartis for the commercial and clinical supply of lentiviral vectors used to generate CTL019 (tisagenlecleucel) and other undisclosed Chimeric Antigen Receptor T cell (CART) products. The agreement builds on the collaboration announced between Oxford BioMedica and Novartis in October 2014 and anticipates the commercial launch of CTL019 (tisagenlecleucel-T) later this year.
- The supply agreement is for three years, extendable to five years subject to the agreement of both parties.
- Under the terms of the agreement which includes minimum offtake requirements, Oxford BioMedica could potentially receive in excess of $100 million from Novartis over the next three years. This amount includes a $10 million upfront payment, various performance incentives and bioprocessing and development services. In addition to this, and as previously announced in October 2014, Oxford BioMedica will also receive undisclosed royalties on potential future sales of Novartis’s CAR-T products.